Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.

Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant.

[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug...